Ad copy

I've reviewed 6,000+ biomarker panels in 16 years as a longevity physician. And when a man in his fifties comes to me with rising PSA, prostate symptoms, and early erectile dysfunction, I don't see three separate problems. I see one man, on one curve, with sixteen to twenty years left before the curve becomes a cliff. He doesn't know that. His urologist doesn't tell him. His primary care doctor manages the symptoms one at a time. And the pharmaceutical interventions he's offered — Tamsulosin for the urinary side, sildenafil for the sexual side — bend the curve in the wrong direction, faster than aging alone would. My name is Dr. Henry Caldwell. I'm a longevity physician. I trained in internal medicine, then in functional and preventive medicine, and I've spent the last sixteen years running a practice focused on one question: what does the next twenty years of this man's body look like, and what can we do today to make that twenty years longer and better? I don't treat prostates. I don't treat erections. I treat trajectories. And here's what I want to tell you about the trajectory you're on right now. If you're in your fifties or sixties and you've started noticing your prostate, your sleep is interrupted by trips to the bathroom, your stream isn't what it used to be, and your erections have started failing — you are not experiencing aging. You are experiencing the standard decline curve. And the standard decline curve is not a natural process. It's a disease process that medicine has simply gotten used to calling "aging" because almost every man in modern life goes through it. I want to show you the math, because the math is what changed my practice. I started tracking my patients' biomarkers longitudinally — the same patients, the same panels, year after year, over a decade — and what I found was that BPH symptoms and ED in men in their fifties were the most reliable single predictor of cardiovascular events in their sixties. More reliable than LDL. More reliable than blood pressure. More reliable than family history. Not because the prostate and the penis are causing the heart problem, but because all three are downstream of the same underlying decline — vascular dysfunction, hormonal cascade, and chronic inflammation — and the prostate and penile arteries are simply the smallest, most sensitive places where the decline shows up first. Your prostate is the most exposed pressure gauge on your circulatory and hormonal system. Your erections are the second-most exposed. By the time those two systems are showing symptoms, your underlying decline curve is already steeper than it should be for your age. And the conventional medical response — Tamsulosin and sildenafil — is treating the two pressure gauges while the underlying disease keeps accelerating underneath. I had this conversation a thousand times before I had it with myself. When my own prostate symptoms started at 54, I knew exactly what they meant. I track my own biomarkers every quarter. I have a coronary calcium score, a fasting insulin, a hs-CRP, a DHEA-S, a free testosterone-to-estradiol ratio, a homocysteine, a fasting lipid panel, and a fasting glucose updated more often than most men get an annual physical. I knew where my curve was. I knew it was bending faster than I wanted it to. And I knew the symptoms in my urinary tract and my erectile tissue were the body's most polite, most early way of telling me about it. My internist offered me Tamsulosin. Standard protocol. I declined. Not because Tamsulosin is bad medicine. It does what it does — it relaxes the muscle around the prostate for ten to twelve hours so you can urinate more easily. It is precisely the intervention that the symptom calls for in a patient who only wants symptom relief. But the symptom isn't the disease. And in a longevity framework, treating the symptom while the disease continues is not just suboptimal — it actively shortens the curve. Let me explain why, because most men don't understand the biology of what's actually happening inside their prostate and erectile tissue. I'll give you the same explanation I give my patients in their second visit, when they're ready to hear it. Your prostate isn't enlarging randomly. Your erections aren't failing randomly. They're the same disease process. Same three root causes. Destroying both organs at the same time, on the same timeline. The first cause is DHT overproduction. After the age of 40, your body converts testosterone into dihydrotestosterone — DHT — at an accelerating rate. DHT acts on prostate tissue the way fertilizer acts on a lawn — it stimulates uncontrolled growth, year after year, decade after decade. By the time a man is in his mid-fifties, the prostate has typically doubled or tripled in size from its baseline. The same DHT cascade disrupts the delicate hormonal environment that erectile function depends on. One hormonal shift. Two organs failing. This is not aging. This is a treatable endocrine dysregulation. The second cause is vascular dysfunction. Your prostate is fed by an intricate network of small vessels. When the lining of those vessels begins to fail — endothelial dysfunction, the same process that causes the cardiovascular events I track in my fifty-year-olds — the prostate tissue starves of oxygen. Chronic hypoxia triggers compensatory inflammation. The prostate swells. The urethra narrows. The same vascular failure destroys your erectile tissue. The penis requires massive, on-demand blood flow to function. When the pelvic vasculature can't dilate properly, erections become weak, unreliable, then impossible. Again — one disease, two organs. The third cause is chronic NF-κB-mediated inflammation. This is the cellular fire that smolders underneath everything I've described. Year after year, NF-κB activation drives prostate tissue proliferation and fibrosis. The tissue thickens. The urethra closes further. The same inflammatory cascade destroys your body's capacity to produce nitric oxide — the signaling molecule that makes erections possible. Without nitric oxide, the lock has no key. The same fire burning two systems. Tamsulosin addresses none of these. Zero. It relaxes the muscle around your prostate for ten to twelve hours. Then it wears off. The DHT is still converting. The vascular dysfunction is still progressing. The inflammation is still smoldering. Your prostate keeps growing. Your erections keep failing. You feel just enough relief at the urinary symptom to believe you're being treated, while the disease curve continues to steepen underneath. In longevity medicine, we call this *delaying without bending* — a class of interventions that postpones a symptom without changing the underlying trajectory. Tamsulosin is a textbook example. Sildenafil is another. They are useful for symptom relief in patients who don't have access to or interest in upstream intervention. For patients who do, they are the wrong tool. What I went looking for was an upstream intervention. Something that addressed the three root causes simultaneously, in both organs, at the molecular level. I found it in a 2024 study published in *Naunyn-Schmiedeberg's Archives of Pharmacology* on a Tuesday night in November. I was reading on my couch with a coffee. I had been searching for a multi-target approach to BPH for months. The study described capsaicin — the active compound in cayenne pepper — activating TRPV1 receptors in endothelial cells, prostate tissue, and erectile tissue simultaneously. TRPV1 activation triggers sustained nitric oxide release. Nitric oxide causes vasodilation and inhibits hypoxia-driven tissue proliferation. The exact mechanism for all three BPH pathways and erectile restoration. Capsaicin treatment reduced prostate weight by 31%. Decreased inflammatory markers including NF-κB and COX-2. Improved endothelial nitric oxide synthase expression. Inhibited 5α-reductase activity simultaneously. And restored erectile function by re-establishing nitric oxide production in penile tissue. All three root causes. Both organs. One compound. The multi-target intervention I had been looking for, hiding in the most consumed spice on Earth. I sat there at 11:43 PM on a Tuesday running the implications. Capsaicin activates TRPV1 receptors throughout the pelvic vascular system. Continuous nitric oxide release across the entire vascular tree. Natural sustained vasodilation in both prostate and erectile tissue. The oxygen-starved tissue gets fresh blood. The inflammation calms. The prostate swelling reduces. The erectile tissue starts producing nitric oxide again. And the compound simultaneously inhibits 5α-reductase, which means it regulates DHT conversion at the source. All three root causes addressed by one mechanism, in both organs. This is exactly the kind of intervention I look for in longevity medicine — a single compound that bends multiple aging curves at once, rather than treating one symptom while another worsens. The next morning I started the deeper search. Not for cayenne capsules from a health food store. Capsaicin is fat-soluble — stomach acid destroys most of it before it reaches the bloodstream unless it's pre-dissolved in the right lipid carrier. Most capsaicin products on the market use cheap inflammatory seed oils — soybean, safflower, sunflower — that drive arterial inflammation and work against the active compound. The wrong carrier doesn't just blunt the effect; it actively contributes to the disease the compound is meant to address. I found Aurivita Capsaicin Power. Three milligrams of pharmaceutical-grade capsaicin per softgel, pre-dissolved in cold-pressed avocado oil. BioPerine added to slow hepatic breakdown. K2 to prevent calcium deposition during vascular repair. Beetroot extract for additional nitric oxide support. Hawthorn for cardiac support. Korean ginseng for adaptogenic stress modulation. Not a trace amount to justify a label. The therapeutic dose used in the research, in the correct carrier, with the supporting compounds I would have formulated myself if I were building it from scratch. I ordered it. I started taking it the day it arrived — three softgels with dinner. Day 10. I woke up at 5:47 AM. Not because I needed to urinate. Because sunlight was coming through the window. I lay there for a moment running the diagnostic — the kind of biomarker I track in my own practice. Six hours of uninterrupted sleep. The first time in fourteen months. Week 3. Standing over the toilet on a Saturday morning. A strong, steady stream. No hesitation. No stopping and starting. I noted the change the way I note any data point — quietly, precisely, without celebration. Then I caught myself smiling. Week 4. Morning erection on waking. The first one in over a year. I tested it for what it was, the way I would test any biomarker, then went back to sleep. Month 2. I ran my own follow-up panel. Flow rate increased from 8 ml/s to 17 ml/s. Post-void residual reduced from 140ml to 25ml. Free testosterone-to-estradiol ratio improved by 14%. Fasting insulin down. hs-CRP down. PSA stable. Erectile function fully restored. This is what an actual upstream intervention looks like in the data. Multiple curves bending in the same direction, in the same patient, over the same eight weeks, from a single compound. I started recommending it to patients in my practice who fit the profile. Men in their fifties and sixties with rising PSA, BPH symptoms, ED, and a coronary calcium score that told me they were already on the standard decline curve. James. 72. Had a Rezum procedure scheduled. His baseline coronary calcium score was 412. He hadn't performed sexually in 18 months. He started Aurivita and tracked his own biomarkers monthly. By week 6, his stream was stronger, his erections had returned, his fasting glucose had dropped 14 points, and his hs-CRP had halved. He cancelled the Rezum and continues to track quarterly. David. 71. Six years on Tamsulosin, maximum dose, failing. Coronary calcium score 218, ankle-brachial index 0.79 — moderate peripheral artery disease. He started Aurivita and within six weeks his flow rate had doubled, his morning erections had returned, and his ankle-brachial index had improved to 0.91. His own primary care doctor asked him for the supplement name. Michael. 67. Six years on Flomax, retrograde ejaculation, severely impaired sexual function. We worked together to taper off Tamsulosin gradually while initiating Aurivita. Within ten weeks his urinary symptoms had improved beyond what the Tamsulosin had been managing, his ejaculation had normalized, and his erectile function had returned to a level he hadn't experienced since his fifties. His statement to me at his three-month follow-up: "I got the next twenty years of my life back." That phrase is the framing that defines longevity medicine, and it's the framing I want you to hold onto. You are not deciding whether to treat a urinary symptom or an erection problem. You are deciding what your next twenty years look like. The standard decline curve, untreated, takes a man from "managing" BPH with Tamsulosin at 55, to dose increases at 60, to acute urinary retention and emergency catheterization at 65, to TURP or HoLEP at 67, to lifelong incontinence and erectile dysfunction at 68, to the cardiovascular event in the early seventies that the urinary and erectile symptoms had been quietly predicting since the fifties. A 2018 European study found that 57% of men on Tamsulosin for more than five years required surgical intervention anyway. After years of prescriptions, side effects, dose increases — surgery anyway. And 45 to 70% of those men lost erectile function permanently after the procedure. 52% reported regret. This is the standard curve. This is what aging looks like in the absence of upstream intervention. It is not natural. It is not inevitable. It is the predictable outcome of treating symptoms while the disease compounds. The alternative is what I do in my practice. Identify the three root causes — DHT, vascular dysfunction, NF-κB inflammation — at the earliest visible expression, which in most men is BPH plus ED in their fifties. Address all three simultaneously with the multi-target intervention that the 2024 research has now validated. Track the biomarkers quarterly. Bend the curve while it can still be bent. Aurivita Capsaicin Power costs $54 for a 60-day supply. Less than $1 a day. Compare it to the cumulative cost of Tamsulosin and sildenafil over five years, which typically exceeds $3,000. Compare it to a TURP or HoLEP procedure, which runs $8,000 to $25,000 in the U.S. and which 52% of recipients regret. Compare it to the cost of the cardiovascular event the standard curve predicts. It comes with a 120-day money-back guarantee. That's three full months. If your stream isn't stronger, if your sleep isn't improving, if your morning erections aren't returning, if your relevant biomarkers aren't moving in the right direction, send back the bags — even empty — for a full refund. I have never seen a pharmaceutical intervention come with that kind of guarantee. I have never seen a surgical procedure come with one. The reason this product comes with one is that it operates on the disease, not on three separate symptoms, and the people behind it can afford to give you four months to prove it to yourself in your own biomarkers. If you're tracking your data the way I track mine, that's all the assurance you need. If you're not tracking your data, this is the moment to start — because the curve you're on right now is the curve you'll regret in fifteen years, and the curve I'm describing is the one your sixty-five-year-old self will thank you for choosing. Bend the curve now, while there's still time to bend it. https://aurivita.co/products/cayenne-pepper-softgels Dr. Henry Caldwell, MD Longevity Physician, 16 years Functional and Preventive Medicine P.S. The biomarkers I'd recommend tracking before and after: PSA, free testosterone, DHT, estradiol, hs-CRP, fasting insulin, HbA1c, coronary calcium score, and a uroflowmetry with post-void residual if your physician will order it. These give you the objective picture of whether the intervention is working at the level of the disease, not just at the level of the symptom. The men in my practice who track this way do not wonder whether the supplement is working — they know, because the numbers show them. P.P.S. You are still inside the window. You're still urinating, even with a weak stream. You're still getting some erections, even if they're inconsistent. Your tissue has not yet crossed the threshold where the damage becomes permanent. But every quarter on the standard curve narrows the window further. The men who bend the curve in their fifties keep functions their peers lose in their sixties. The men who wait until their sixties to bend the curve usually find the window has closed. Twelve weeks. Three biomarker checks. One decision. The data will tell you what to do.